Mitoxantrone hydrochloride (NSC-310739) in lymphoma - A Southwest Oncology Group study

Charles A. Coltman; Terri M. McDaniel; Stanley P. Balcerzak; Francis S. Morrison; Daniel D. Von Hoff

doi:10.1007/BF00180193

Mitoxantrone hydrochloride (NSC-310739) in lymphoma - A Southwest Oncology Group study

Charles A. Coltman, Terri M. McDaniel, Stanley P. Balcerzak, Francis S. Morrison, Daniel D. Von Hoff

Resultado de la investigación: Article › revisión exhaustiva

41 Citas (Scopus)

Resumen

The members of the Southwest Oncology Group have treated thirteen patients with Hodgkin's disease and thirty-seven with non-Hodgkin's lymphoma with mitoxantrone on the every three week schedule. While the result (\313 responses in Hodgkin's; \937 responses in non-Hodgkin's lymphoma) is not striking, there is a definite antitumor activity in a very heavily pretreated group of patients. Toxicity was acceptable. Additional trials in lymphoma are planned using mitoxantrone in combination with BCNU.

Idioma original	English (US)
Páginas (desde-hasta)	65-70
Número de páginas	6
Publicación	Investigational New Drugs
Volumen	1
N.º	1
DOI	https://doi.org/10.1007/BF00180193
Estado	Published - mar 1983
Publicado de forma externa	Sí

ASJC Scopus subject areas

Oncology
Pharmacology
Pharmacology (medical)

Acceder al documento

10.1007/BF00180193

Otros archivos y enlaces

Citar esto

@article{091751b672e1416c9750fa858d3ad307,

title = "Mitoxantrone hydrochloride (NSC-310739) in lymphoma - A Southwest Oncology Group study",

abstract = "The members of the Southwest Oncology Group have treated thirteen patients with Hodgkin's disease and thirty-seven with non-Hodgkin's lymphoma with mitoxantrone on the every three week schedule. While the result (\313 responses in Hodgkin's; \937 responses in non-Hodgkin's lymphoma) is not striking, there is a definite antitumor activity in a very heavily pretreated group of patients. Toxicity was acceptable. Additional trials in lymphoma are planned using mitoxantrone in combination with BCNU.",

keywords = "Hodgkin's disease, mitoxantrone, non-Hodgkin's lymphoma",

author = "Coltman, {Charles A.} and McDaniel, {Terri M.} and Balcerzak, {Stanley P.} and Morrison, {Francis S.} and {Von Hoff}, {Daniel D.}",

year = "1983",

month = mar,

doi = "10.1007/BF00180193",

language = "English (US)",

volume = "1",

pages = "65--70",

journal = "Investigational New Drugs",

issn = "0167-6997",

publisher = "Kluwer Academic Publishers",

number = "1",

}

TY - JOUR

T1 - Mitoxantrone hydrochloride (NSC-310739) in lymphoma - A Southwest Oncology Group study

AU - Coltman, Charles A.

AU - McDaniel, Terri M.

AU - Balcerzak, Stanley P.

AU - Morrison, Francis S.

AU - Von Hoff, Daniel D.

PY - 1983/3

Y1 - 1983/3

N2 - The members of the Southwest Oncology Group have treated thirteen patients with Hodgkin's disease and thirty-seven with non-Hodgkin's lymphoma with mitoxantrone on the every three week schedule. While the result (\313 responses in Hodgkin's; \937 responses in non-Hodgkin's lymphoma) is not striking, there is a definite antitumor activity in a very heavily pretreated group of patients. Toxicity was acceptable. Additional trials in lymphoma are planned using mitoxantrone in combination with BCNU.

AB - The members of the Southwest Oncology Group have treated thirteen patients with Hodgkin's disease and thirty-seven with non-Hodgkin's lymphoma with mitoxantrone on the every three week schedule. While the result (\313 responses in Hodgkin's; \937 responses in non-Hodgkin's lymphoma) is not striking, there is a definite antitumor activity in a very heavily pretreated group of patients. Toxicity was acceptable. Additional trials in lymphoma are planned using mitoxantrone in combination with BCNU.

KW - Hodgkin's disease

KW - mitoxantrone

KW - non-Hodgkin's lymphoma

UR - http://www.scopus.com/inward/record.url?scp=0020919569&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0020919569&partnerID=8YFLogxK

U2 - 10.1007/BF00180193

DO - 10.1007/BF00180193

M3 - Article

C2 - 6678857

AN - SCOPUS:0020919569

SN - 0167-6997

VL - 1

SP - 65

EP - 70

JO - Investigational New Drugs

JF - Investigational New Drugs

IS - 1

ER -

Mitoxantrone hydrochloride (NSC-310739) in lymphoma - A Southwest Oncology Group study

Resumen

ASJC Scopus subject areas

Acceder al documento

Otros archivos y enlaces

Huella

Citar esto